TIMP1 and COVID-19: Thus, larger samples are needed to obtain a better evaluation of TIMP-1 levels circulating levels as a prognostic biomarker in COVID-19 patients and to investigate its potential role in monitoring therapeutic response in different treatment subgroups of COVID-19 patients.